Rankings
▼
Calendar
TERN Q2 2020 Earnings Report — Terns Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
Terns Pharmaceuticals, Inc.
TERN
Q2 2020 Earnings
Reported June 29, 2020
Quarter Comparison
Revenue
Operating Income
EPS (Diluted)
Free Cash Flow
Metric
Q2 2020
Q1 2020
Q2 2019
QoQ Change
YoY Change
Revenue
$0
—
—
—
—
Op. Income
-$10M
—
—
—
—
EPS (Diluted)
$-0.40
—
—
—
—
Free Cash Flow
-$9M
—
—
—
—
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$0
Cost of Revenue
$0
GROSS PROFIT
$0
R&D Expenses
$8M
Selling & Marketing
$0
General & Administrative
$2M
SG&A Expenses
$2M
Other Expenses
$0
Operating Expenses
$10M
Cost & Expenses
$10M
OPERATING INCOME
-$10M
Interest Income
$2.0K
Interest Expense
$0
Other Income/Expenses
$252.0K
INCOME BEFORE TAX
-$10M
Income Tax Expense
$0
Net Income from Continuing Ops
-$10M
Net Income from Discontinued Ops
$0
Other Adjustments
$0
NET INCOME
-$10M
Net Income Deductions
$0
BOTTOM LINE NET INCOME
-$10M
D&A
$99.0K
EBIT
-$10M
EBITDA
-$10M
EPS
-$0
EPS Diluted
-$0
marketcaparena.com
Cash Flow Statement
Item
Amount
Net Income
-$10M
Depreciation & Amortization
$99.0K
Stock-Based Compensation
$0
Deferred Income Tax
$1.0K
Other Non-Cash Items
$33.0K
Change in Working Capital
$733.0K
OPERATING CASH FLOW
-$9M
Capital Expenditure
-$102.0K
Acquisitions (Net)
$0
Purchases of Investments
$0
Sales/Maturities of Investments
$0
Other Investing Activities
$0
NET CASH FROM INVESTING
-$102.0K
Net Debt Issuance
$17M
Common Stock Repurchased
$0
Common Dividends Paid
$0
Other Financing Activities
$0
NET CASH FROM FINANCING
$17M
FREE CASH FLOW
-$9M
Net Change in Cash
$0
marketcaparena.com
← FY 2019
TERN Overview
Q1 2021 →